Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy

Molecular Cancer Therapeutics

Volumn 9, Issue 8, 2010, Pages 2243-2254

  Albanese, Clara ^a   Alzani, Rachele ^a   Amboldi, Nadia ^a   Avanzi, Nilla ^a   Ballinari, Dario ^a   Brasca, Maria Gabriella ^a   Festuccia, Claudio ^b   Fiorentini, Francesco ^a   Locatelli, Giuseppe ^a   Pastori, Wilma ^a   Patton, Veronica ^a   Roletto, Fulvia ^a   Colotta, Francesco ^a   Galvani, Arturo ^a   Isacchi, Antonella ^a   Moll, Jurgen ^a   Pesenti, Enrico ^a   Mercurio, Ciro ^c   Ciomei, Marina ^a  

^a Cell Biology Department   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c Genextra Group   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; N,1,4,4 TETRAMETHYL 8 [[4 (4 METHYLPIPERAZIN 1 YL)PHENYL]AMINO] 4,5 DIHYDRO 1H PYRAZOLO[4,3 H]QUINAZOLINE 3 CARBOXAMIDE; PHA 848125; PROTEIN KINASE; RETINOBLASTOMA PROTEIN; TROPOMYOSIN RECEPTOR KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG BLOOD LEVEL; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TUMOR BIOPSY; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; HUMANS; MICE; MULTIGENE FAMILY; PHOSPHORYLATION; PROTEIN KINASES; PYRAZOLES; QUINAZOLINES; RATS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955495586     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0190     Document Type: Article

References (50)

1. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004;18:2699-711.
2. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31. (Pubitemid 33741897)
3. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
4. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
5. Benson C, Kaye S, Workman P, Garrett M, Walton M, De Bono J. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer 2005;92:7-12.
6. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004;5: 27-36.
7. Slingerland J, Pagano M. Regulation of the Cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-7. (Pubitemid 30130220)
8. Desdouets C, Bréchot C. p27: a pleiotropic regulator of cellular phenotype and a target for cell cycle dysregulation in cancer. Pathol Biol 2000;48:203-10.
9. Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25-31.
10. Santamaria D, Barriere C, Cerqueira A, et al. CDK1 is sufficient to drive the mammalian cell cycle. Nature 2007;448:811-5.
11. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-45. (Pubitemid 37443879)
12. Campaner S, Doni M, Hydbring P, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010; 12:54-9.
13. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003;13:1775-85.
14. Mendez J. Cell proliferation without cyclin E-Cdk2. Cell 2003;114: 398-9. (Pubitemid 37100988)
15. Kozar K, Ciemerych MA, Rebel VI, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004;118:477-91.
16. McInnes C. Progress in the evaluation of CDK inhibitors as antitumor agents. Drug Discov Today 2008;13:875-81.
17. Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol 1994;25:1386-403.
18. Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett 2006;232:90-8.
19. Lannon CL, Sorensen PH. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol 2005;15:215-23.
20. Festuccia C, Muzi P, Gravina GL, et al. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol 2007;30:193-200.
21. Ketterer K, Rao S, Friess H, Weiss J, Büchler MW, Korc M. Reverse transcription-PCR analysis of laser-captured cells point to potential paracrine and autocrine actions of neurotrophins in pancreatic cancers. Clin Cancer Res 2003;9:5127-36.
22. Lagadec C, Meignan S, Adriaenssens E, et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009;28:1960-70.
23. Davidson B, Reich R, Lazarovici P, et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003;9:2248-59.
24. Montano X, Djamgoz M. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett 2004;571:1-8. (Pubitemid 38992914)
25. Brasca MG, Albanese C, Amici R, et al. 6-Substituted pyrrolo[3,4-c] pyrazoles: an improved class of CDK2 inhibitors. Chem Med Chem 2007;2:841-52.
26. Brasca MG, Amboldi N, Ballinari D, et al. Identification of N,1,4,4- tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro- 1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, oral available cyclin dependent kinase inhibitor. J Med Chem 2009;52:5152-63.
27. Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 2000;45:140-8.
28. Pevarello P, Brasca MG, Amici R, et al. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem 2004;47:3367-80.
29. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68.
30. Radaelli E, Ceruti R, Patton V, et al. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol 2009;24:879-91.
31. Simeoni M, Magni P, Cammia C, et al. Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004;64:1094-101.
32. Jang TJ, Kang MS, Kim DH, Lee JI, Kim JR. Increased expression of cyclin D1, cyclin E and p21 (Cip1) associated with decreased expression of p27(Kip1) in chemically induced rat mammary carcinogenesis. Jpn J Cancer Res 2000;91:1222-32.
33. Golay J, Di Gaetano N, Amico D, et al. Gentuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 2005;128:310-7.
34. Giavazzi R, Di Berardino C, Garofalo A, et al. Establishment of human acute myelogenous leukemia lines secreting interleukin-1β in SCID mice. Int J Cancer 1995;61:280-5.
35. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-5. (Pubitemid 23211439)
36. 1/S cyclin-dependent kinases. J Biol Chem 1997;272:12738-46.
37. Knudsen ES, Wang JYJ. Differential regulation of retinoblastoma protein function by specific cdk phosphorylation sites. J Biol Chem 1996;271:8313-20.
38. Hassler M, Singh S, Yue WW, et al. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction, and holoprotein architecture. Mol Cell 2007;28: 371-85.
39. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
40. DePinto W, Chu X, Yin X, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical study. Mol Cancer Ther 2006;5:2644-58.
41. 2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo activity in tumor models. Mol Cancer Ther 2007;6:926-34.
42. Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther 2009;8:324-32.
43. Byth KF, Thomas A, Hughes G, et al. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2 and 9 leads to pharmacodynamic changes and potent antitumor effects in human xenografts. Mol Cancer Ther 2009;8:1856-66.
44. Tibes R, Jimeno A, Von Hoff D. Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125 [abstract 3531]. ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:3531.
45. Reuther GW, Lambert QT, Caligiuri MA, Der CD. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol Cell Biol 2000;20:8655-66.
46. Tacconelli A, Farina AR, Cappabianca I, Giulino A, Mackay AR. Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. Future Oncol 2005;1:689-98.
47. Zhu Z, Friess H, DiMola F, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 1999;17:2419-28.
48. Melamed I, Levy J, Parvari R, Gelfand EW. A novel lymphocyte signaling defect: trkA mutation in the syndrome of congenital insensitivity to pain and anhidrosis (CIPA). J Clin Immunol 2004;24: 441-8. (Pubitemid 39005577)
49. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005;65:9426-35.
50. Morgensztern D, Belani CP. Novel cytotoxic agents. J Thorac Oncol 2009;4:S1082-3.